Open-label Phase I of 89Zr-girentuximab (89Zr-TLX250) to Assess the Safety, Biodistribution, Pharmacokinetics and Sensitivity/Specificity of PET/CT Images in Patients With Suspected Renal Cell Carcinoma Including Clear Cell Renal Cell Carcinoma (ZIRDAC-JP Study)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Girentuximab Zr-89 (Primary)
Indications Carcinoma; Renal cancer
Focus Adverse reactions; Diagnostic use
Acronyms ZIRDAC-JP

Most Recent Events

18 Aug 2021 Status changed from recruiting to completed.
21 Apr 2021 According to a Telix Pharmaceuticals media release, the study data (Phase I component ) was reviewed by the studys independent Data and Safety Monitoring Board (DSMB).
21 Apr 2021 Results of phase I (n=6) presented in a Telix Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight